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Background: Recent technological advances have stimulated the development of endoscopic optical biopsy
technologies. This study compared the accuracy of endoscopic diagnosis using magnifying narrow-band imaging
(NBI) and histologic diagnosis of esophageal squamous lesions.
Methods: Patients at high risk for esophageal squamous cell carcinoma were examined with endoscopy and
subsequent biopsy. The lesions diagnosed as cancer on NBI and the lesions diagnosed as cancer on biopsy were
resected endoscopically or surgically. Histological diagnoses of resected specimens, the reference standards in this
study, were made by a pathologist who was blind to both the endoscopic and biopsy diagnoses. The primary
outcome was the accuracy of endoscopic and biopsy diagnosis. A noninferiority trial design with a noninferiority
margin of −10% was chosen to investigate the accuracy of endoscopic diagnosis using magnifying NBI.
Results: Between November 2010 and October 2012, a total of 111 lesions in 85 patients were included in the
analysis. The accuracy of endoscopic diagnosis and biopsy diagnosis for all lesions was 91.0% (101/111) and 85.6%
(95/111), respectively. The difference in diagnostic accuracy was 5.4% (95% confidence interval: −2.9%–13.7%). The
accuracy of endoscopic diagnosis and biopsy diagnosis of invasive cancers was 94.9% (74/78) and 84.6% (66/78),
respectively. The difference was 10.3% (95% confidence interval: 1.6%–19.0%) for invasive cancers. The lower bound
of the 95% confidence interval was above the prestated −10% in both cases.
Conclusion: Noninferiority of endoscopic diagnosis by magnifying NBI to histologic diagnosis by biopsy was
established in this study (p = 0.0001).
Trial registration: The study was registered on 9th November 2010 in the University Hospital Medical Network
Clinical Trials Registry as number: UMIN000004529.
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Esophageal cancer is the sixth most common cause of
cancer-related mortality worldwide [1]. The overall survival
of patients with esophageal cancer, regardless of histological
type, remains poor. However, a favorable prognosis can be
expected if this cancer is detected at an early stage [2-5].* Correspondence: isihara-ry@mc.pref.osaka.jp
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unless otherwise stated.Diagnosis of early esophageal cancers is based on the
detection of suspicious lesions and histological evaluation
of specimens taken from these suspicious lesions.
Endoscopically or surgically resected specimens with
total biopsy of the lesions would provide the most accurate
histologic diagnosis and can serve as the reference standard
of histologic diagnosis. There are reports of discrep-
ancy between diagnosis based on biopsy specimens and
diagnosis based on endoscopically resected specimens,
suggesting limited accuracy of biopsy diagnosis [6,7]. A
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Figure 1 A lesion with well-demarcated brownish change of
the epithelium and scattered brown dots.
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Such limitations in the accuracy of biopsy diagnosis may
be associated with the sampling process or diagnostic
process for small specimens. Taking 3 to 10 biopsy speci-
mens would improve the accuracy of this technique
[10-13]. However, multiple biopsies can increase the risk
and cost of the procedure and potentially make subse-
quent endoscopic resection difficult [14-16].
Recent technological advances have stimulated the
development of numerous optical methods. These methods
allow for accurate evaluation and diagnosis of cancers
in vivo and are thus termed optical biopsy techniques.
Endoscopic optical biopsy techniques offer noninvasive
real-time diagnosis. Some techniques currently being
evaluated include optical coherence tomography [17,18],
endocytoscopy [19], and narrow-band imaging (NBI)
[20]. NBI is an imaging technique that enhances the
visualization of mucosal microstructures and microves-
sels. Previous studies involving NBI and magnification
have shown high diagnostic accuracy for esophageal
squamous cell carcinoma [21-24]. Although many endo-
scopic techniques have preliminarily shown high accur-
acy rates, these technologies are still evolving, and the
accuracy of endoscopic diagnosis has not yet been fully
investigated. Endoscopic diagnosis has the advantage of
providing noninvasive and real-time diagnosis without
the additional cost of biopsy. If the accuracy of endoscopic
diagnosis is comparable to that of histologic diagnosis of
biopsy specimens, endoscopic optical biopsy can be used
in some situations. However, few studies have compared
the accuracy of endoscopic optical diagnosis with that of
histologic biopsy diagnosis.
This study compared the accuracy of endoscopic diag-
nosis using magnifying NBI versus histologic diagnosis of
esophageal squamous lesions. The accuracy was evaluated
using lesions diagnosed as cancer on biopsy and lesions
endoscopically diagnosed as cancer. Histologic diagnosis
of resected specimens served as the reference standard.
A noninferiority trial design was adopted under the
consideration that a similar or slightly reduced accuracy
of endoscopic diagnosis might be accepted because it
would be balanced by other benefits such as less invasive-
ness, less cost, and real-time results.
Methods
Patients
The study protocol was approved by the Ethics Committee
of the Osaka Medical Center for Cancer and Cardiovascular
Diseases. The study was registered in the University
Hospital Medical Network Clinical Trials Registry
(UMIN-CTR) as number UMIN 000004529. The patient
inclusion criteria were the presence of esophageal neopla-
sia, a history of esophageal cancer treated by endoscopic
resection, and current or past head and neck cancer.Patients were excluded if they had undergone previous
surgery, chemotherapy, or radiotherapy for esophageal
cancer. Patients were also excluded if they had severe
reflux esophagitis or an allergy to iodine.
Endoscopic examinations and biopsies
The endoscopic procedures were carried out using a high-
resolution magnifying upper gastrointestinal endoscope
(GIF-Q240Z or GIF-FQ260Z; Olympus, Tokyo, Japan) or
a high-definition magnifying upper gastrointestinal endo-
scope (GIF-H260Z; Olympus). The structure-enhancement
function of the video processor was set at a level of B8
(strongest enhancement level for microstructures) for NBI
observation. A black soft hood (MB-162 for GIF-Q240Z
and MB-46 for FQ260Z and GIF-H260Z; Olympus)
was mounted on the tip of the endoscope to maintain
an adequate distance between the tip of the endoscope
zoom lens and the mucosal surface during magnifying
observation. Initial routine inspection was carried out
with white-light imaging. The surface vascular pattern
of the lesion was then observed by magnifying NBI.
These procedures were followed by chromoendoscopy
with iodine solution.
Endoscopic diagnosis using magnifying NBI was made
as follows. Cancer was diagnosed when well-demarcated
brownish change of the epithelium and scattered brown
dots or dilated, tortuous vessels of various sizes were
identified (Figure 1) [24,25]. An undetermined status was
assigned when an obscure brownish change or obscure
scattered brown dots were present (Figure 2). The absence
of cancer was diagnosed when no brownish change or
scattered brown dots were present (Figure 3). Biopsy spec-
imens were taken from iodine-unstained lesions or lesions
that were diagnosed as cancer or undetermined on NBI.
Figure 2 A lesion with obscure brownish change and obscure
scattered brown dots.
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analysis because endoscopic observation and biopsy of
these lesions are usually difficult. Lesions of ≤5 mm were
also excluded from the analysis because most of them
would likely be removed by biopsy. The endoscopic re-
ports, which included lesion sizes but not endoscopic
diagnoses, were sent to the pathologist. Biopsy specimens
were embedded in paraffin and subjected to staining
with hematoxylin and eosin. Pathologists with special
qualifications made histological diagnoses of cancer
based on structural and cytological abnormalities.
Endoscopic resection and histologic assessment
The lesions diagnosed as cancer on NBI and the lesions
diagnosed as high-grade intraepithelial neoplasia orFigure 3 A lesion without any dilated and tortuous vessels.cancer on biopsy were resected endoscopically or surgi-
cally. Lesions were also resected when they showed an
obvious pink color change after iodine staining [26,27].
Resected specimens were embedded in paraffin and sub-
jected to hematoxylin and eosin staining. Another path-
ologist with special qualifications (S.I.) who was blind to
the endoscopic and biopsy diagnoses made the histo-
logical diagnoses according to the WHO criteria for the
classification of early gastrointestinal neoplasia [28]. Le-
sions with structural and cytological abnormalities reach-
ing the upper half of the squamous epithelium were
diagnosed as cancer in situ, also termed high-grade
intraepithelial neoplasia [28]. The lesions were also diag-
nosed as cancer based on obvious cytological abnormal-
ities of the squamous epithelium, even when the
abnormalities were confined to the lower half of the squa-
mous epithelium [29]. The depth of cancer involvement
was classified according to the Japanese Classification of
Esophageal Carcinoma [29]. Written informed consent
was obtained from all patients prior to enrollment.
Statistical analysis
The index lesion for the study was squamous cell car-
cinoma, including carcinoma in situ. For the statistical
analysis, the histological results of resected specimen
served as the reference standard. Evaluation was performed
on a per-lesion basis, and the lesion was considered to be
the unit of analysis. For patients with more than one lesion,
each lesion was considered to be an independent observa-
tion for statistical purposes.
The primary outcome variable in this study was the
accuracy of endoscopic diagnosis and biopsy diagnosis.
The specificity, positive predictive value (PPV), negative
predictive value (NPV), and accuracy were calculated
as follows: Sensitivity = correctly diagnosed cancers/total
cancers; Specificity = correctly diagnosed noncancers/total
noncancers; PPV = total cancers/total lesions diagnosed as
cancers; NPV = total noncancers/total lesions diagnosed
as noncancers; and Accuracy = correctly diagnosed lesions/
total lesions.
A noninferiority trial design was chosen to investigate
the accuracy of endoscopic diagnosis using magnifying
NBI. In a noninferiority trial, a slightly reduced diagnostic
accuracy might be accepted if it is balanced by other sec-
ondary benefits; in the case of optical biopsy using magni-
fying NBI, these benefits include less invasiveness, less
cost, and real-time results. Noninferiority of endoscopic
diagnosis is established when the difference between
endoscopic diagnosis and biopsy diagnosis is not smaller
than the prespecified noninferiority margin. We chose a
noninferiority margin (D) of −10% at the outset of this
trial because we considered that this level would balance
the clinical efficacy and secondary benefits. Previous stud-
ies have reported that the diagnostic accuracy of optical
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Therefore, we hypothesized that optical biopsy diagnosis
and histological diagnosis of biopsy specimens would
achieve an accuracy of 90%. The study required at least
110 lesions for a 10% threshold of noninferiority and a
statistical power of 80% with statistical significance set
at p < 0.05. McNemar’s test was used to compare the
accuracy of endoscopic diagnosis and biopsy diagnosis.
For all analyses, a p value of <0.05 was considered statisti-
cally significant.
Subgroup analysis was performed to compare the
outcomes among subgroups divided according to lesion
size and cancer invasion depth (cancer in situ or invasive
cancer) to confirm the consistency of the results.
Results
Primary endpoint
Between November 2010 and October 2012, a total of
300 patients who fulfilled our criteria underwent endo-
scopic examination (Figure 4). A total of 193 lesions were
detected in these patients, and 111 lesions in 85 patients
were included in the analysis. Of the 111 lesions, 100
lesions were diagnosed as HGIN or cancer by magnifyingFigure 4 Patient disposition.NBI. Eight lesions were diagnosed as undetermined by
magnifying NBI but as cancer by histologic diagnosis of
the biopsy specimens. Two lesions were diagnosed as no
cancer by magnifying NBI but as cancer by histologic
diagnosis of the biopsy specimens. One lesion was diag-
nosed as no cancer by magnifying NBI and histologic
diagnosis of the biopsy specimens but as cancer by iodine
staining.
A single biopsy specimen was taken from the lesion in
105 of the 111 lesions, and 2 biopsy specimens were
taken from the other 6 lesions. Of the 111 lesions, 78
were invasive cancer, 32 were intraepithelial cancer, and
1 was low-grade intraepithelial neoplasia. The median
(range) lesion size was 20 mm (6–100 mm). In total, 23
lesions were located in the upper esophagus, 63 were in
the mid-esophagus, and 25 were in the lower esophagus.
The accuracy, sensitivity, and specificity of endoscopic
diagnosis by magnifying NBI were 91.0% (101/111)
(95% CI: 84.1%–95.6%), 90.9% (100/110) (95% CI:
83.9%–95.6%), and 100% (1/1) (95% CI: 2.5%–100.0%),
respectively (Table 1). The accuracy, sensitivity, and
specificity of histologic diagnosis of biopsy specimens
were 85.6% (95/111) (95% CI: 77.7%–91.5%), 86.4%
(95/110) (95% CI: 78.5%–92.2%), and 0% (0/1) (95% CI:
0.0%–97.5%), respectively (Table 1). The difference in
diagnostic accuracy was 5.4% (95% CI: −2.9%–13.7%).
The lower bound of the 95% confidence interval was
above the prestated −10%; thus, the primary endpoint was







Value (95% CI†) 90.9% (83.9–95.6%) 86.4% (78.5–92.2%)
No.lesions 100/110 95/110
Specificity
Value (95% CI) 100% (2.5–100.0) 0% (0.0–97.5%)
No.lesions 1/1 0/1
Positive predictive value
Value (95% CI) 100% (96.4–100.0%) 99.0% (94.3–100.0%)
No.lesions 100/100 95/96
Negative predictive value
Value (95% CI) 9.1% (0.2–-41.3%) 0% (0–21.8%)
No.lesions 1/11 0/15
Accuracy
Value (95% CI) 91.0% (84.1–95.6%) 85.6% (77.7–91.5%)
No.lesions 101/111 95/111
†CI: confidence interval.
Figure 6 White-light imaging shows a reddish lesion 20 mm in
diameter on the posterior wall of the lower esophagus.
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men was established (p = 0.0001) (Figure 5).
Subgroup analysis
The accuracy of endoscopic diagnosis in lesions ≤10 and
>10 mm was 77.8% (21/27) (95% CI: 57.7%–91.4%) and
95.2% (80/84) (95% CI: 88.3%–98.7%), respectively. The
accuracy of histologic diagnosis of biopsy specimens in
lesions ≤10 and >10 mm was 74.1% (20/27) (95% CI:
53.7%–88.9%) and 89.3% (75/84) (95% CI: 80.6%–95.0%),
respectively. The difference in the diagnostic accuracy was
3.7% (95% CI: −20.4%–27.8%, p = 0.13) in lesions ≤10 mm
and 6.0% (95% CI: −1.7%–13.7%, p < 0.0001) in
lesions >10 mm.
The accuracy of endoscopic diagnosis in epithelial le-
sions and invasive cancers was 81.8% (27/33) (95% CI:
64.5%–93.0%) and 94.9% (74/78) (95% CI: 87.4%–98.6%),
respectively. The accuracy of histologic diagnosis of biopsy
specimens in epithelial lesions and invasive cancers was
87.9% (29/33) (95% CI: 71.8%–96.6%) and 84.6% (66/78)
(95% CI: 74.7%–91.8%), respectively. The difference in the
diagnostic accuracy was −6.1% (95% CI: −24.8%–12.7%,
p = 0.34) in epithelial lesions and 10.3% (95% CI: 1.6%–
19.0%, p < 0.0001) in invasive cancers. With the exception
of intraepithelial lesions, endoscopic diagnosis showed
results preferable to those of histologic diagnosis of biopsy
specimens, and the consistency of the results was con-
firmed in the subgroup analyses.
Retrospective analysis of misdiagnosis
Retrospective analysis of 15 cancers misdiagnosed as no
cancer by biopsy was performed (Figure 6,7,8 and 9).
Cytological abnormalities were confirmed in 13 of the 15
lesions. Of these 13 lesions with cytological abnormalities,
11 were misdiagnosed because the atypia was weak, and 2
were misdiagnosed because of concomitant inflammation.Figure 5 Accuracy of biopsy diagnosis and endoscopic
diagnosis in all lesions.Another two lesions were probably misdiagnosed due to
sampling error because no cytological abnormalities were
observed in the biopsy specimens.
Retrospective analysis of 10 cancers endoscopically
misdiagnosed as undetermined or no cancer was per-
formed. Of these 10 lesions, vascular change was not
obvious in 4, brownish change of the epithelium was not
obvious in 2, neither of these changes was obvious in 3,
and the mucosal surface was not observed because of
extensive keratosis in 1.
Discussion
The accuracy of endoscopic diagnosis and biopsy diag-
nosis was 91.0% (101/111) (95% CI: 84.1%–95.6%) and
85.6% (95/111) (95% CI: 77.7%–91.5%). The difference in
diagnostic accuracy was 5.4% (95% CI: −3.9%–13.8%),
and the noninferiority of endoscopic diagnosis by magni-
fying NBI to histologic diagnosis by biopsy was established
(p < 0.001). Our study is unique because lesions diagnosed
as cancer by endoscopic and biopsy examination were
included in the study. This study is the first to show the
accuracy of endoscopic diagnosis compared with biopsy
diagnosis using a noninferiority trial design.
Diagnosis of gastrointestinal cancers is based on the
detection of suspicious lesions and histological evaluation
of biopsy specimens taken from these suspicious lesions.
Although biopsy diagnosis serves as the gold standard
pretreatment diagnosis, it is associated with high false-
negative rates [8,9]. False-negative biopsy diagnosis may
occur secondary to error in the specimen retrieval
process. However, in this study, all biopsies were taken
from the lesions, which was confirmed by recorded
pictures. Focally distributed cancer can be missed by
biopsy, even if the specimen is taken from the lesion.
Figure 7 Narrow-band imaging shows well-demarcated brownish
change of the epithelium and the presence of scattered
brown dots.
Figure 9 Histologic diagnosis of a resected specimen was
cancer in situ.
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biopsy, this sampling error is a basic limitation of biopsy
rather than technical error.
A single biopsy specimen was taken from the lesion in
105 of 111 lesions and from all 15 lesions with a false-
negative biopsy diagnosis. Multiple biopsies may improve
the accuracy of biopsy diagnosis. In previous reports, 3 to
4 biopsies [10], 4 to 6 biopsies [12], and 10 biopsies [13]
are recommended to obtain high diagnostic accuracy.
Multiple biopsies are acceptable for patients with advanced
cancers that will be treated by surgical resection. However,
multiple biopsies may cause problems for patients with
early cancers because submucosal fibrosis caused by
multiple biopsies sometimes interferes with the endoscopic
resection process. Considering the potential disadvantage ofFigure 8 Biopsy diagnosis of cancer was not made because
of inflammation.multiple biopsies, the importance of endoscopic diagnosis
rather than multiple biopsies for superficial lesions should
be emphasized.
In recent years, several new endoscopic imaging
techniques have been developed that may improve the
detection and diagnosis of early esophageal cancer. NBI is
a novel imaging technique that enhances the visualization
of mucosal microstructures and microvessels. The addition
of the magnification component has further allowed
visualization of very minute mucosal details and hence
histologic prediction in real time. Previous studies of NBI
and magnification have shown a high diagnostic accuracy
for esophageal squamous cell carcinoma, raising the ex-
pectation of optical biopsy in the clinical setting. However,
the accuracy of endoscopic diagnosis has not been directly
compared with that of other modalities. Before it can be
regarded as a useful modality for diagnosis of cancer, it
should be compared with the current standard modality
of biopsy diagnosis. Therefore, we conducted the current
study and showed the noninferiority of endoscopic diag-
nosis compared with the accuracy of biopsy diagnosis.
This study was conducted based on the assumption that
biopsy diagnosis and endoscopic diagnosis are tested
modalities and that only histologic diagnosis of resected
specimens can be regarded as the reference standard.
Based on these assumptions, unresected lesions were
not included in the analysis because the reference stand-
ard of the resected specimens was not obtained in these
lesions. However, even if those lesions were included as
noncancer, the noninferiority of endoscopic diagnosis
was established.
A noninferiority trial design was chosen to investigate
the utility of endoscopic diagnosis compared with biopsy
diagnosis. In a noninferiority trial, a slightly reduced
clinical efficacy might be accepted if it is balanced by
other secondary benefits; in the case of endoscopic
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lower cost, and real-time results. We chose a stringent
and conservative noninferiority margin (Δ) of 10% [30]
and showed the noninferiority of endoscopic diagnosis
compared with biopsy diagnosis. In this study, lesions
with obvious cytological abnormalities were diagnosed
as cancer even when they were confined to the lower
half of the squamous epithelium. There are some issues
regarding the diagnosis of these lesions. In Western
countries, these lesions are diagnosed as low-grade
intraepithelial neoplasia and are not diagnosed as cancer.
Therefore, we conducted subgroup analysis of invasive
cancers. Noninferiority of the endoscopic diagnosis to
biopsy diagnosis was also confirmed in this subgroup.
Subgroup analyses were also performed among sub-
groups divided according to lesion size and intrae-
pithelial lesions. The accuracy of endoscopic diagnosis
was comparable with that of biopsy diagnosis in all
subgroups, thus enhancing the reliability of the study
conclusions.
This study is limited because all lesions were not con-
firmed by the reference standard of resected specimens.
Considering the risk of endoscopic resection or surgical
resection, resecting lesions diagnosed as noncancer by
endoscopy or biopsy would not be acceptable.
Conclusions
This study showed that the accuracy of endoscopic
diagnosis is comparable with that of biopsy diagnosis.
This finding may facilitate the practical use of endoscopic
optical diagnosis.
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